IgE-Mediated Disorders: Current Therapeutics and New Strategies Involving Synthetic Peptides

ISSN: 1875-614X (Online)
ISSN: 1871-5230 (Print)

Volume 16, 3 Issues, 2017

Download PDF Flyer

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Formerly: Current Medicinal Chemistry - Anti-Inflammatory and Anti-Allergy Agents

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Submit Abstracts Online Submit Manuscripts Online

Claudiu T. Supuran
Neurofarba Department
University of Florence

View Full Editorial Board

Subscribe Purchase Articles Order Reprints

IgE-Mediated Disorders: Current Therapeutics and New Strategies Involving Synthetic Peptides

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, 7(4): 252-263.

Author(s): Antonio Verdoliva and Maria Rossi.

Affiliation: TECNOGEN S.p.A., Localita La Fagianeria, 81013 Piana di Monte Verna (CE), Italy.


Most of the current therapies for the treatment of atopic diseases are based on drugs that inhibit or suppress components of the allergic inflammatory response. Antihistamines, bronchodilators, antiallergic drugs and corticosteroids remain by far the most effective therapeutic response to allergic diseases in reducing symptoms and concomitant inflammatory reactions. The last two decades witnessed a large number of works aimed at identifying medications targeting specific steps in the allergic cascade. Because the binding of IgE to mast cells via the high affinity surface mast cell receptor (FcεRI) is the central event in allergic manifestations, its inhibition seems the best approach for designing innovative antiallergic drugs. Progress has been made on the molecular level by using anti-IgE and anti-FcεRI antibodies, or chimeric proteins targeting Fc receptors. Nevertheless, validation of IgE and FcεRI as crucial targets for allergic disorders is provided by a wealth of studies where the antiallergic activity of small molecules, such as peptides, able to inhibit IgE/FcεRI interaction, was assessed. D-PAM, a tetrameric IgE-binding tripeptide, derived through combinatorial chemistry, represents a new and innovative mechanism for atopy treatment. Due to its polycationic structure, this peptide is active in in vitro (β- hexosaminidase release) and in vivo (passive and active cutaneous anaphylaxis) models of allergy, without interfering with IgE/FcεRI or IgE/Ag interaction, thus opening the way to development of new antiallergic drugs.


Allergic disorders, IgE, FcεRI, antiallergic drugs, mast cell degranulation.

Purchase Online Order Reprints Order Eprints Rights and Permissions

Article Details

Volume: 7
Issue Number: 4
First Page: 252
Last Page: 263
Page Count: 12
DOI: 10.2174/187152308786847843
Price: $58

Related Journals

Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science